Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Molecular Imaging of High-Risk Atherosclerotic Plaques: Is It Clinically Translatable?

  • Hwang, Byung-Hee (Cardiovascular Center and Cardiology Division, Seoul St. Mary's Hospital) ;
  • Kim, Myung-Hee (Cardiovascular Center and Cardiology Division, Seoul St. Mary's Hospital) ;
  • Chang, Kiy-Uk (Cardiovascular Center and Cardiology Division, Seoul St. Mary's Hospital)
  • Published : 2011.09.30
⟨ Previous Next ⟩

Abstract

The explosive epidemics of diabetes and obesity as well as an aging population have led to cardiovascular diseases as the leading cause of world-wide morbidity and mortality beyond cancer. The recent introduction of drug-eluting stents and medications such as statins, dual anti-platelet therapy, and angiotensin converting enzyme inhibitors has dramatically improved clinical outcomes in patients with cardiovascular diseases. However, mortality is still increasing despite state-of-the-art therapeutics, as current diagnostic and therapeutic strategies against cardiovascular disease center on "locking the barn door after the horse has been stolen". Novel diagnostic solutions that identify individuals at risk before the disease is overt are needs. Imaging approaches that visualize molecular targets rather than anatomical structures aim to illuminate vital molecular and cellular aspects of atherosclerosis biology in vivo. Recent technological advances in small animal imaging systems and dedicated targeted/activatable molecular imaging probes have positioned molecular imaging to greatly impact atherosclerosis imaging in the next decade. However, several issues must be addressed before its clinical translation.

Keywords

References

  1. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41. https://doi.org/10.1016/j.jacc.2009.10.015
  2. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndrome: a collaborative meta-analysis of randomized trials. JAMA 2005;293:2908-17. https://doi.org/10.1001/jama.293.23.2908
  3. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomized trial: randomized Intervention Trial of unstable Angina. Lancet 2002;360:743-51. https://doi.org/10.1016/S0140-6736(02)09894-X
  4. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16. https://doi.org/10.1056/NEJMoa070829
  5. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation 2004;110:278-84. https://doi.org/10.1161/01.CIR.0000135468.67850.F4
  6. Sinusas AJ, Bengel F, Nahrendorf M, et al. Multimodality cardiovascular molecular imaging, part I. Circ Cardiovasc Imaging 2008;1:244-56. https://doi.org/10.1161/CIRCIMAGING.108.824359
  7. Nahrendorf M, Sosnovik DE, French BA, et al. Multimodality cardiovascular molecular imaging, part II. Circ Cardiovasc Imaging 2009;2:56-70. https://doi.org/10.1161/CIRCIMAGING.108.839092
  8. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 2008;451:953-7. https://doi.org/10.1038/nature06803
  9. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38. https://doi.org/10.1016/j.jacc.2009.09.009
  10. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weiss-leder R. Cellular imaging of inflammation in atherosclerosis using ma-gnetofluorescent nanomaterials. Mol Imaging 2006;5:85-92.
  11. Trivedi RA, Mallawarachi C, U-King-Im JM, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 2006;26:1601-6. https://doi.org/10.1161/01.ATV.0000222920.59760.df
  12. Lee K, Moon HY, Park C, et al. Magnetic resonance imaging of ma-crophage activity in atherosclerotic plaques of apolipoprotein E-deficient mice by using polyethylene glycolated magnetic fluorescent silica-coated nanoparticles. Curr Appl Phys 2009;9:S15-8. https://doi.org/10.1016/j.cap.2008.08.040
  13. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708-11. https://doi.org/10.1161/01.CIR.0000020548.60110.76
  14. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission to-mography. J Am Coll Cardiol 2006;48:1825-31. https://doi.org/10.1016/j.jacc.2006.03.069
  15. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010;30:1282-92. https://doi.org/10.1161/ATVBAHA.108.179739
  16. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006;47(8 Suppl):C7-12. https://doi.org/10.1016/j.jacc.2005.09.068
  17. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006;69:625-35. https://doi.org/10.1016/j.cardiores.2005.11.003
  18. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003;108:1664-72. https://doi.org/10.1161/01.CIR.0000087480.94275.97
  19. Chang K, Jaffer F. Advances in fluorescence imaging of the cardiovascular system. J Nucl Cardiol 2008;15:417-28. https://doi.org/10.1016/j.nuclcard.2008.03.001
  20. Jaffer FA, Vinegoni C, John MC, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 2008;118:1802-9. https://doi.org/10.1161/CIRCULATIONAHA.108.785881
  21. Jaffer FA, Calfon MA, Rosenthal A, et al. Two-dimensional intravascular near-infrared fluorescence molecular imaging of inflammation in atherosclerosis and stent-induced vascular injury. J Am Coll Cardiol 2011;57:2516-26. https://doi.org/10.1016/j.jacc.2011.02.036
  22. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 2010;10:36-46. https://doi.org/10.1038/nri2675
  23. Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis. Circ Res 2010;107:839-50. https://doi.org/10.1161/CIRCRESAHA.110.224766
  24. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011;145:341-55. https://doi.org/10.1016/j.cell.2011.04.005
  25. Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid artery atherosclerosis. N Engl J Med 2004;350:1472-3.
  26. Jeziorska M, Woolley DE. Neovascularization in early atherosclerotic lesions of human carotid arteries: its potential contribution to plaque development. Hum Pathol 1999;30:919-25. https://doi.org/10.1016/S0046-8177(99)90245-9
  27. Michel JB, Virmani R, Arbustini E, Pasterkamp G. Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J 2011;32:1977-85. https://doi.org/10.1093/eurheartj/ehr054

Cited by

  1. Nanosensors for early cancer detection and for therapeutic drug monitoring vol.10, pp.23, 2011, https://doi.org/10.2217/nnm.15.180
  2. Ex vivo detection of macrophages in atherosclerotic plaques using intravascular ultrasonic-photoacoustic imaging vol.62, pp.2, 2017, https://doi.org/10.1088/1361-6560/aa4f6b